Paracetamol IV Market Size, Share & Trends Analysis Report By Indication (Pain, Pyrexia), By Application (Surgical, Non-surgical), By End Use (Hospitals, Clinics), By Region (North America, Asia Pacific), And Segment Forecasts, 2025 - 2030

Paracetamol IV Market Size, Share & Trends Analysis Report By Indication (Pain, Pyrexia), By Application (Surgical, Non-surgical), By End Use (Hospitals, Clinics), By Region (North America, Asia Pacific), And Segment Forecasts, 2025 - 2030


Nuclear Imaging Equipment Market Growth & Trends

The global nuclear imaging equipment market size is expected to reach USD 7.91 billion by 2030, registering a CAGR of 3.23% from 2025 to 2030, according to a new report by Grand View Research, Inc. The primary factor contributing to the market is the increasing prevalence of chronic diseases and the growing demand for accurate and early diagnostic techniques. Nuclear imaging devices play a pivotal role in the diagnosis of conditions such as cancer, cardiovascular diseases, and neurological disorders, contributing to the expanding applications of these technologies in clinical settings.

Numerous technological advancements and ongoing research and development activities also play a pivotal role in driving market growth. A notable example is the introduction of hybrid imaging systems that integrate nuclear imaging with other modalities such as computed tomography (CT) and magnetic resonance imaging (MRI). These integrated solutions provide comprehensive diagnostic information, giving more efficient and precise patient assessments. For instance, as reported in an article by Siemens Healthcare in April 2023, doctors in Brazil and Argentina discovered that upgrading their PET/CT scanners not only enabled them to effectively address new patient demands and alleviate scheduling pressures but also surpassed expectations by creating opportunities to explore new areas of care.

Moreover, the aging population is a significant factor contributing to the growing demand for nuclear imaging in healthcare. As the elderly population is more prone to various health issues, there is an increase in the requirement for accurate diagnostic tools capable of aiding in the early detection and monitoring of age-related diseases.For instance, according to the World Health Organization (WHO), it is projected that by the year 2030, one in six people worldwide will be aged 60 years or over. This demographic shift emphasizes the increasing prevalence of an aging population and underscores the importance of advanced diagnostic tools, such as nuclear imaging, in addressing the healthcare needs of this demographic group.

Nuclear Imaging Equipment Market Report Highlights
  • On the basis of modality, the single photon emission computed tomography (SPECT) segment dominated the market with the largest revenue share of 57.88 % in 2024. A key contributing factor is the cost-effectiveness associated with SPECT equipment and procedures.
  • On the basis of application, the oncology segment dominated the market with the largest revenue share of 48.99% in 2024. This is due to the growing prevalence of cancer worldwide and advanced nuclear imaging technology, notably PET and SPECT have seen significant expansion owing to their unmatched capability to thoroughly examine the molecular traits specific to cancer.
  • The cardiology segment is expected to grow at the fastest rate from 2025 to 2030. The rising incidence of cardiovascular diseases (CVDs) coupled with the increased awareness regarding nuclear imaging's diagnostic capabilities is anticipated to fuel market growth.
  • Among end-use, the hospitals segment captured the largest revenue share of 51.96% in 2024. Hospitals are adopting nuclear imaging equipment at an increasing rate.
  • In 2024, the North America nuclear imaging equipment market held a dominant position, capturing a significant share of 42.82%. This trend is expected to continue throughout the forecast period.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Indication
1.2.2. Application
1.2.3. End Use
1.2.4. Regional Scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. Paracetamol IV Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising cases of postoperative pain
3.2.1.2. Increasing prevalence of chronic disorders
3.2.1.3. Increasing use of intravenous paracetamol in combination with NSAIDs and narcotics
3.2.2. Market Restraint Analysis
3.2.2.1. Overdose of paracetamol IV
3.2.2.2. Availability of generic products
3.3. Paracetamol IV Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. Paracetamol IV Market: Indication Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Paracetamol IV Market: Indication Movement Analysis
4.3. Paracetamol IV Market by Indication Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Pain
4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Pyrexia (Fever)
4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Paracetamol IV Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Paracetamol IV Market: Application Movement Analysis
5.3. Paracetamol IV Market by Application Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Surgical
5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Non-surgical
5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Paracetamol IV Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Paracetamol IV Market: End Use Movement Analysis
6.3. Paracetamol IV Market by End Use Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. Hospitals
6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Clinics
6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Others
6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Paracetamol IV Market: Regional Estimates & Trend Analysis
7.1. Regional Dashboard
7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
7.3. North America
7.3.1. U.S.
7.3.1.1. Key country dynamics
7.3.1.2. Regulatory framework/ reimbursement structure
7.3.1.3. Competitive scenario
7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Canada
7.3.2.1. Key country dynamics
7.3.2.2. Regulatory framework/ reimbursement structure
7.3.2.3. Competitive scenario
7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Mexico
7.3.3.1. Key country dynamics
7.3.3.2. Regulatory framework/ reimbursement structure
7.3.3.3. Competitive scenario
7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.4. Europe
7.4.1. UK
7.4.1.1. Key country dynamics
7.4.1.2. Regulatory framework/ reimbursement structure
7.4.1.3. Competitive scenario
7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Germany
7.4.2.1. Key country dynamics
7.4.2.2. Regulatory framework/ reimbursement structure
7.4.2.3. Competitive scenario
7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. France
7.4.3.1. Key country dynamics
7.4.3.2. Regulatory framework/ reimbursement structure
7.4.3.3. Competitive scenario
7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.4.4. Italy
7.4.4.1. Key country dynamics
7.4.4.2. Regulatory framework/ reimbursement structure
7.4.4.3. Competitive scenario
7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.4.5. Spain
7.4.5.1. Key country dynamics
7.4.5.2. Regulatory framework/ reimbursement structure
7.4.5.3. Competitive scenario
7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.4.6. Norway
7.4.6.1. Key country dynamics
7.4.6.2. Regulatory framework/ reimbursement structure
7.4.6.3. Competitive scenario
7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.4.7. Sweden
7.4.7.1. Key country dynamics
7.4.7.2. Regulatory framework/ reimbursement structure
7.4.7.3. Competitive scenario
7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.4.8. Denmark
7.4.8.1. Key country dynamics
7.4.8.2. Regulatory framework/ reimbursement structure
7.4.8.3. Competitive scenario
7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Asia Pacific
7.5.1. Japan
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework/ reimbursement structure
7.5.1.3. Competitive scenario
7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. China
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/ reimbursement structure
7.5.2.3. Competitive scenario
7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.5.3. India
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/ reimbursement structure
7.5.3.3. Competitive scenario
7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.5.4. Australia
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/ reimbursement structure
7.5.4.3. Competitive scenario
7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.5.5. South Korea
7.5.5.1. Key country dynamics
7.5.5.2. Regulatory framework/ reimbursement structure
7.5.5.3. Competitive scenario
7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.5.6. Thailand
7.5.6.1. Key country dynamics
7.5.6.2. Regulatory framework/ reimbursement structure
7.5.6.3. Competitive scenario
7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Latin America
7.6.1. Brazil
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework/ reimbursement structure
7.6.1.3. Competitive scenario
7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Argentina
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/ reimbursement structure
7.6.2.3. Competitive scenario
7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.7. MEA
7.7.1. South Africa
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework/ reimbursement structure
7.7.1.3. Competitive scenario
7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. Saudi Arabia
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/ reimbursement structure
7.7.2.3. Competitive scenario
7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. UAE
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/ reimbursement structure
7.7.3.3. Competitive scenario
7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Kuwait
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/ reimbursement structure
7.7.4.3. Competitive scenario
7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.2. Recent Developments & Impact Analysis by Key Market Participants
8.3. Company Market Share Analysis, 2024
8.4. Key Company Profiles
8.4.1. Mallinckrodt (Mallinckrodt Pharmaceuticals)
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Cipla Inc.
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Lupin
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Dr. Reddy's Laboratories Ltd.
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Aurobindo Pharma
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Sun Pharmaceutical Industries Ltd.
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Novartis AG
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Pfizer, Inc.
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Abbott
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Sanofi
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
8.4.11. Bristol-Myers Squibb Company
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product benchmarking
8.4.11.4. Strategic initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings